Supporting Information

Thermo/pH responsive star and linear copolymers containing a cholic acid-derived monomer, *N*-Isopropylacrylamide and acrylic acid: synthesis and study of solution behavior

Ana Castro-Hernández and Norma Aidé Cortez-Lemus*

Centro de Graduados e Investigación en Química. Tecnológico Nacional de

México/Instituto Tecnológico de Tijuana. A. P. 1166. Tijuana, B. C., C.P. 22000, México.

E-mail: <u>ncortez@tectijuana.mx</u>

Index

Contents		Page
Synthesis of a	a cholic acid-derived monomer CAE	2
Figure S1.	¹ H-NMR (400 MHz) spectrum of 2-(acryloyloxy)ethyl cholate (CAE) in CDCl ₃ .	3
Synthesis of CTA's 1 to 3		3
Synthesis of CTA-2		3
Figure S2	¹ H-NMR (400 MHz) spectrum of bromide precursor from CTA- 1 -Br in CDCl ₃ .	5
Figure S3	¹³ C-NMR (100 MHz) spectrum of bromide precursor from CTA- 1 - Br in CDCl ₃ .	6
Figure S4	¹ H-NMR (400 MHz) spectrum of CTA-1 in CDCI ₃ .	6
Figure S5	¹³ C-NMR (100 MHz) spectrum of CTA-1 in CDCl ₃ .	7
Figure S6	¹ H-NMR (400 MHz) spectrum of bromide precursor from CTA- 2 -Br in CDCl ₃ .	8
Figure S7	¹³ C-NMR (100 MHz) spectrum of bromide precursor from CTA- 2 - Br in CDCl ₃ .	9
Figure S8	¹ H-NMR (400 MHz) spectrum of CTA- 2 in CDCl ₃ .	9
Figure S9	¹³ C-NMR (100 MHz) spectrum of CTA-2 in CDCl ₃ .	10
Figure S10	¹ H-NMR (400 MHz) spectrum of tetrafunctional bromide precursor CTA- 3- Br in CDCl ₃ .	11
Figure S11	¹³ C-NMR (100 MHz) spectrum of tetrafunctional bromide precursor CTA- 3 -Br in CDCl ₃	11
Figure S12	¹ H-NMR (400 MHz) spectrum of CTA- 3 in CDCI ₃ .	12
Figure S13	¹³ C-NMR (100 MHz) spectrum of CTA- 3 in CDCI ₃ .	13
Synthesis of RAFT)	macroCTA's (polymerization of PCAE using the CTA's 1 to 3 by	14
Synthesis of	PCAE ₃ - <i>b</i> -PEG ₄₅ - <i>b</i> -PCAE ₃ or macroCTA-1	14
Figure S14	¹ H-NMR (400 MHz) spectrum of macroCTA-1 in CDCl ₃ .	15
Synthesis of (GE7-b-PCAE4)3 or macroCTA-2		

Figure S15	¹ H-NMR (400 MHz) spectrum of macroCTA- 2 in CDCl ₃ .	16	
Synthesis of (PCAE ₂) ₄ or macroCTA-3	16	
Figure S16	¹ H-NMR (400 MHz) spectrum of macroCTA- 3 in CDCl ₃ /CD ₃ OD.	17	
Chain extens	sion polymerization of NIPAM with or without acrylic acid in	18	
presence of the macroCTA's			
Figure S17	¹ H-NMR (400 MHz) spectrum of PNIPAM ₁₂₀ - <i>b</i> -PCAE ₃ - <i>b</i> -PEG ₄₅ -	18	
	b-PCAE ₃ -b-PNIPAM ₁₂₀ in CDCI ₃ .		
Figure S18	¹ H-NMR (400 MHz) spectrum of PAAc _{2%} -co-PNIPAM ₁₄₇ -b-	19	
	PCAE ₃ - <i>b</i> -PEG ₄₅ - <i>b</i> -PCAE ₃ - <i>b</i> -PNIPAM ₁₄₇ - <i>co</i> -PAAc _{2%} in CDCl ₃ .		
Figure S19	¹ H-NMR (400 MHz) spectrum of (GE ₇ - <i>b</i> -PCAE ₄ - <i>b</i> -PNIPAM ₇₉) ₃ in	20	
	CDCl ₃ .		
Figure S20	¹ H-NMR (400 MHz) spectrum of (GE ₇ - <i>b</i> -PCAE ₄ - <i>b</i> -PNIPAM ₅₉ - <i>co</i> -	20	
	AAc _{2%}) ₃ in CDCl ₃ .		
Figure S21	¹ H-NMR (400 MHz) spectrum of (PCAE ₂ - <i>b</i> -PNIPAM ₇₅) ₄	21	
-	copolymer in CDCl ₃ .		
Figure S22	¹ H-NMR (400 MHz) spectrum of (PCAE ₂ - <i>b</i> -PNIPAM ₉₃ - <i>co</i> -AAc _{2%}) ₄	21	
	copolymer in CDCl ₃ .		
Figure S23	Hydrodynamic diameter (Dh) for (GE7-b-PCAE4-b-PNIPAM79)3	22	
-	copolymer at different concentrations (0.5 to 8 mg/mL in PBS) by		
	DLS at 25 °C.		
References		22	

EXPERIMENTAL SECTION

Synthesis of a cholic acid-derived monomer CAE. The synthesis of CAE was carried out following the methodology reported by De and co-workers [1].



Figure S1. ¹H-NMR (400 MHz) spectrum of 2-(acryloyloxy)ethyl cholate (CAE) in CDCl₃.

2-(acryloyloxy)ethyl cholate (CAE). ¹H NMR (CDCl₃, 400 MHz), δ (ppm): 6.44-6.48 (C*H*₂=CHCO trans, 1H, dd, *J*₁=17.2 Hz, *J*₂=1.2), 6.20-6.13 (COC*H*=CH₂, 1H, dd, *J*₁=17.2 Hz, *J*₂=10.40), 5.90-5.87 (C*H*₂=CHCO cis, 1H, dd, *J*₁=10.4 Hz, *J*₂=1.2), 4.40-4.33 (COO-C*H*₂C*H*₂-OCO, 4H, m), 3.99 (12'-C*H*, 1H, m), 3.88 (7'-C*H*, 1H, m), 3.48 (3'-C*H*, 1H, m), 1.01 (21'-C*H*₃, 3H, d, *J*=6.28), 0.92 (19'-C*H*₃, 3H, s) and 0.71 (18'-C*H*₃, 3H, s), R_f = 0.30 (1:1 ethyl acetate:CH₂Cl₂).

Synthesis of CTA's 1 to 3

Synthesis of CTA-**2**. Step 1: *Synthesis of bromide precursor*. Glycerol ethoxylate (4 g, 0.004 mol) was dissolved in dry THF (45 mL) and pyridine was then added (1.105 g, 0.014 mol). This solution was ice-cooled and 2-bromopropionyl bromide (1.46 mL, 0.014 mol in

5 mL of dry THF) was added dropwise. After complete addition, the mixture reaction was maintained in ice for 1 h. The solution was stirred at room temperature overnight. The amine salt formed was filtered off and the filtrated was concentrated under reduced pressure. Next, the product was dissolved in 50 mL of CH₂Cl₂ and HCl (30 mL, 0.01 M) was added to the solution (X3). Next, NaHCO₃ (30 mL, 0.01 M). The reaction mixture was dried with Na₂SO₄. After evaporation of solvent under reduced pressure, the bromide precursor of CTA-**2** was purified using column chromatography on silica gel (CH₂Cl₂:CH₃OH, 4:1). 2.5 g of yellowish liquid was obtained.

Step 2: Dodecanethiol (0.86 g, 4.26 mmol) was dissolved in THF (15 mL) and triethylamine (0.32 g, 4.26 mmol) was added to the reaction mixture. After 10 min, CS₂ was added dropwise (0.61 mL, 4.26 mmol). Next, the bromide trifunctional precursor was added to the yellow solution (1.5 g, 1.065 mmol) and stirred overnight at room temperature. After remove the amine salt, the yellow filtrated was evaporate under reduced pressure. Finally, the trithiocarbonate was purified using column chromatography on silica gel (CH₂Cl₂:CH₃OH, 5:1). 2.5 g of yellow oil thick was obtained. Note: The synthesis of CTA **1** and **3** was following this methodology but using poly(ethylene glycol) (2000 g/mol) and PERT respectively, for the synthesis of the brominate precursors.

4



Figure S2. ¹H-NMR (400 MHz) spectrum of bromide precursor from CTA-1-Br in CDCl₃.

CTA-1-Br. ¹H NMR (CDCl₃, 400 MHz), δ (ppm): 4.43-4.36 (CH₃C*H*Br, 2H, q, *J*= 7.2 Hz and *J*= 6.8 Hz), 4.32 (O=CO-C*H*₂-CH₂-, 4H, t, *J*= 4.8 Hz), 3.73 (-CH₂-C*H*₂-O, 4H, t), 3.66 (-C*H*₂C*H*₂-O, 181H, s), 1.82 (C*H*₃CHBr, 6H, d, *J*= 7.2 Hz) (See Fig. S2). ¹³C NMR (CDCl₃): 170.2 (*C*=O), 70.6 (-*C*H₂*C*H₂-O), 68.8 (O=CO-*C*H₂-CH₂-, 65.0 (-CH₂-*C*H₂-O), 39.9 (CH₃*C*HBr), 21.6 (*C*H₃CHBr) (See Fig. S3).



Figure S3. ¹³C-NMR (100 MHz) spectrum of bromide precursor from CTA-1-Br in CDCl₃.



Figure S4. ¹H-NMR (400 MHz) spectrum of CTA-1 in CDCl₃.

CTA-1. ¹H NMR (CDCl₃, 400 MHz), δ (ppm): 4.88-4.79 (CH₃-CH-S, q, 2H, *J*= 7.2 Hz and *J*= 7.2 Hz), 4.29 (-(CH₂-CH₂)-O-CH₂-CH₂-O-, 4H, t, *J*= 4.8 Hz), 3.70 (CH₂-CH₂)-O-CH₂-CH₂-O-, t, 4H), 3.66 (-CH₂-CH₂-O, s, 195 H), 3.38-3.31 (-CH₂CH₂-S, td, 4H, *J*= 2.0 Hz and *J*= 5.2 Hz), 1.69 (-S-CH₂-CH₂, q, 4H, *J*= 7.2 Hz), 1.60 (CH₃-CH-S, d, 6H, *J*= 7.2 Hz), 1.47-1.19 (-CH₂CH₂- 38H), 0.88 (CH₃CH₂-, 6H, t, *J*= 6.4 Hz) (See Fig. S4). ¹³C NMR (CDCl₃): 221.9 (C=S), 171.0 (C=O), 70.6 (-CH₂CH₂-O), 68.8 (O=CO-CH₂-CH₂-), 64.9 (O=CO-CH₂-CH₂-O) 16.9 (CH₃CH-S), 14.0 (CH₃CH₂-) (See Fig. S5).





Figure S6. ¹H-NMR (400 MHz) spectrum of bromide precursor from CTA-2-Br in CDCl₃.

CTA-**2**-Br. ¹H NMR (CDCl₃, 400 MHz), δ (ppm): 4.43-4.36 (CH₃C*H*Br, 3H, q, *J*= 6.8 Hz and *J*= 7.2 Hz), 4.31 (-CH₂-CH₂-O-C*H*₂-, 6H, t, *J*= 4.8 Hz), 3.72 (-CH₂-C*H*₂-O-CO, 6H, m), 3.66 (-C*H*₂C*H*₂-O, 88H, s), 1.82 (C*H*₃CHBr, 9H, d, *J*= 6.8 Hz) (See Fig. S6). ¹³C NMR (CDCl₃): 170.2 (*C*=O), 78.35 (*C*H), 69.70 (-*C*H₂*C*H₂-O), 68.70 (-O-*C*H₂-CH₂-), 65.0 (-O-CH₂-*C*H₂-), 39.9 (CH₃CHBr), 21.6 (*C*H₃CHBr) (See Fig. S7).



Figure S7. ¹³C-NMR (100 MHz) spectrum of bromide precursor from CTA-2-Br in CDCl₃.



Figure S8. ¹H-NMR (400 MHz) spectrum of CTA-2 in CDCl₃.

CTA-2. ¹H NMR (CDCl₃, 400 MHz), δ (ppm): 4.90-4.80 (CH₃-C*H*-S, 3H, q, *J*= 7.2 Hz and *J*= 7.2 Hz), 4.31 (-(CH₂-CH₂)-O-CH₂-C*H*₂-O-, 6H, t, *J*= 4.8 Hz), 3.72 (-(CH₂-CH₂)-O-C*H*₂-CH₂-O, 4H, t), 3.66 (-C*H*₂-C*H*₂-O, 94H, s), 3.36 (-CH₂-C*H*₂-S-, 6H, td, *J*= 4.8 Hz), 1.71 (-C*H*₂CH₂-S, q, 6H, *J*= 7.2 Hz), 1.62 (C*H*₃-CH-S, 9H, d, *J*= 7.2 Hz), 1.47-1.20 (-C*H*₂C*H*₂-S-6H), 0.90 (C*H*₃CH₂-, 9H, t, *J*= 6.8 Hz) (See Fig. S8). ¹³C NMR (CDCl₃): 221.9 (*C*=S), 171.1 (*C*=O), 70.6 (-*C*H₂*C*H₂-O), 16.9 (*C*H₃CH-S), 14.0 (*C*H₃CH₂-) (See Fig. S9).



Figure S9. ¹³C-NMR (100 MHz) spectrum of CTA-**2** in CDCl₃.



Figure S10. ¹H-NMR (400 MHz) spectrum of tetrafunctional bromide precursor CTA-**3-**Br in CDCl₃.



Figure S11. ¹³C-NMR (100 MHz) spectrum of tetrafunctional bromide precursor CTA-**3**Br in CDCl₃.

CTA-**3**Br. Tetrafunctional bromide precursor. ¹H NMR (CDCl₃, 400 MHz), δ (ppm): 4.36-4.12 (C*H*₂-OCO and CH₃C*H*Br, 12H, m), 1.76 (C*H*₃CHBr, 12H, d, *J*=6.93) (See Fig. S10). ¹³C NMR (CDCl₃): 169.3 (*C*=O), 63 (*C*H₂-O), 43.2 (-*C*-CH₂-O), 39.3 (CH₃*C*HBr), 21.5 (*C*H₃CHBr) (See Fig. S11). R_f = 0.24 (hexanes:CH₂Cl₂ 1:1).



Figure S12. ¹H-NMR (400 MHz) spectrum of CTA-3 in CDCl₃.



CTA-**3**, Tetrafunctional trithiocarbonate. ¹H NMR (CDCl₃, 400 MHz), δ (ppm): 4.77 (SCS-C*H*-CO, 4H, q, *J*=7.41 Hz), 3.99 (C*H*₂-OCO, 8H, m), 3.28 (C*H*₂-SCS, 8H, t, *J*=7.43 Hz), 1.62 (C*H*₂-CH₂-SCS, 8H, quintet, *J*=7.43 Hz), 1.51 (C*H*₃-CH-SCS, 12H, d, *J*=7.41 Hz), 1.36-1.19 (-(C*H*₂)₈-, 75H, m, aliphatic chain), 0.82 (-CH₂-C*H*₃, 12H, t, *J*= 6.83 Hz) (See Fig. S12). ¹³C NMR (CDCl₃): 221.7 (*C*=S), 170.4 (*C*=O), 62.9 (*C*H₂-O), 47.3 (CH₃*C*H-S), 42.3 (*C*), 37.5 (-*C*H₂-S), 31.9 (-*C*H₂-CH₂-S), 29.7, 29.6, 29.5, 29.3, 29.1, 29 (-*C*H₂-CH₂-CH₂-CH₂-S), 16.4 (*C*H₃CH-S), 14.1 (-*C*H₃) (See Fig. S13). R_f = 0.72 (hexanes:CH₂Cl₂ 1:1).

Synthesis of macroCTA's (polymerization of PCAE using the CTA's 1 to 3 by RAFT) Synthesis of macroCTA-**1** or PCAE₃-*b*-PEG₄₅-*b*-PCAE₃

CTA-1 (162 mg, 0.06 mmol), CAE (0.45 g, 0.888 mmol) and AIBN (2 mg, 0.012 mmol) were dissolved in 2 mL of DMF. The ratio between CAE/CTA-1/AIBN =74/5/1. The solution was de-oxygenated by bubbling nitrogen for 20 min at room temperature. Then, the flask was placed in an oil bath preheated at 68 °C. After 5 h, the polymerization was stopped by cooling to room temperature. The polymerization yield was obtained gravimetrically by adding a three-fold excess of diethyl ether. The polymer was obtained as a yellowish thick liquid (65%); $M_n _{NMR}$ = [(I_{18} /3 (506.68 g/mol) I_{12}] + 2000 g/mol + 698 g/mol= 5,502 g/mol; DP_{PCAE}= 6; $M_{n,GPC}$ =6,036 g/mol, Đ=1.10 (Table 1).

¹H NMR (CDCl₃, 400 MHz), δ (ppm): 4.86 (CH₃-C**H**-S, m, 2H), 4.28 (O-C**H**₂-C**H**₂-O, from PCAE), 3.98 (s, 12' C**H**), 3.84 (s, 7' C**H**), 3.65 (-C**H**₂-C**H**₂-O, s, 184H), 1.0 (s, 19'-C**H**₃), 0.89 (s, 21'-C**H**₃), 0.69 (s, 18'-C**H**₃) (See Fig. S14).



Figure S14. ¹H-NMR (400 MHz) spectrum of macroCTA-1 in CDCl₃.

Synthesis of (GE7-b-PCAE4)3 or macroCTA-2

CTA-**2** (370 mg, 0.181 mmol), CAE (1.3 g, 2.57 mmol) and AIBN (6 mg, 0.036 mmol) were dissolved in 4 mL of DMF. The ratio between CAE/CTA-**1**/AIBN = 71/5/1. The solution was de-oxygenated by bubbling nitrogen for 20 min at room temperature. Then, the flask was placed in an oil bath preheated at 68 °C. After 2 h, the polymerization was stopped by cooling to room temperature. The polymerization yield was obtained gravimetrically by adding a three-fold excess of diethyl ether. The polymer was obtained as a yellowish solid (60%); M_n NMR= [(I_{18} /3 (506.68 g/mol) / I_r /3] + 1,000 g/mol + 1,047 g/mol=7,333 g/mol; DP_{PCAE}=12; $M_{n,GPC}$ =8,519 g/mol, Đ=1.06 (Table 1).

¹H NMR (CDCl₃, 400 MHz), δ (ppm): 4.89 (CH₃-C**H**-S, m, 3H), 4.29 (O-C**H**₂-C**H**₂-O, from PCAE), 3.99 (s, 12' C**H**), 3.85 (s, 7' C**H**), 3.66 (-C**H**₂-C**H**₂-O, s, 87H), 1.01 (s, 19'-C**H**₃), 0.90 (s, 21'-C**H**₃), 0.70 (s, 18'-C**H**₃) (See Fig. S15).



Figure S15. ¹H-NMR (400 MHz) spectrum of macroCTA-2 in CDCl₃.

Synthesis of (PCAE₂)₄ or macroCTA-3

CTA-**3** (176 mg, 0.120 mmol), CAE (1.0 g, 1.97 mmol) and AIBN (4 mg, 0.024 mmol) were dispersed in 3.5 mL of DMF. The ratio between CAE/CTA-**3**/AIBN = 80/5/1. (Note: the CTA-**3** is only partially soluble in DMF, but at 68 °C become part of the solution in the first 3 min). The solution was de-oxygenated by bubbling nitrogen for 20 min at room

temperature. Then, the flask was placed in an oil bath preheated at 68 °C. After 1.5 h, the polymerization was stopped by cooling to room temperature. The polymerization yield was obtained gravimetrically by adding a three-fold excess of diethyl ether. The polymer was obtained as a yellowish solid (44%), M_n NMR= [($I_{18}/3$ (506.68 g/mol)/k/4] + 1465 g/mol=5,079 g/mol; DP_{PCAE}= 2 per arm; $M_{n,GPC}$ =7,200 g/mol, Đ=1.12 (Table 1). MacroCTA-3. ¹H NMR (CDCl₃, 400 MHz), δ (ppm): 4.89 (CH₃-C*H*-S, m, 4H), 4.27 (O-

C*H*₂-C*H*₂-O, from PCAE), 3.93 (s, 12' C*H*), 3.86 (s, 7' C*H*), 3.66 (-C*H*₂-C*H*₂-O, s, 87H), 1.0 (s, 19'-C*H*₃), 0.89 (s, 21'-C*H*₃), 0.69 (s, 18'-C*H*₃) (See Fig. S16).



Figure S16. ¹H-NMR (400 MHz) spectrum of macroCTA-3 in CDCl₃/CD₃OD.

Chain extension polymerization of NIPAM with or without acrylic acid in presence of the macroCTA's (Table 2)

As a representative example, the procedure is described for (PCAE₂-*b*-PNIPAM₉₃-*co*-PAAc_{2%})₄ copolymer (Table 2): macroCTA-**3** (0.064 g, 0.0126 mmol), NIPAM (0.49 g, 4.33 mmol), acrylic acid (0.006 g, 0.0884 mmol), and AIBN (0.36 mg, 0.0022 mmol) were dissolved in 2.5 mL of DMF. The oxygen was removed purged with nitrogen for 15 min. The mixture was heated in an oil bath at 68 °C for 6 h. The polymerization was obtained by adding a three-fold excess of diethyl ether. (PCAE-*b*-PNIPAM-*co*-PAAc_{2%})₄ copolymer product was obtained as a yellowish solid with 73% conv. Table 2, M_{n,GPC}=49,800 g/mol, D=1.28.



Figure S17. ¹H-NMR (400 MHz) spectrum of PNIPAM₁₂₀-*b*-PCAE₃-*b*-PEG₄₅-*b*-PCAE₃-*b*-PCAE

¹H NMR (CDCl₃, 400 MHz), δ (ppm): 7.24-5.75 (-CO-N*H*-), 3.65 (-C*H*₂-C*H*₂-O, s), 0.70 (s, 18'-C*H*₃) (See Fig. S17).



Figure S18. ¹H-NMR (400 MHz) spectrum of PAAc_{2%}-*co*-PNIPAM₁₄₇-*b*-PCAE₃-*b*-PEG₄₅*b*-PCAE₃-*b*-PNIPAM₁₄₇-*co*-PAAc_{2%} in CDCl₃.



Figure S19. ¹H-NMR (400 MHz) spectrum of (GE₇-*b*-PCAE₄-*b*-PNIPAM₇₉)₃ in CDCl₃.



Figure S20. ¹H-NMR (400 MHz) spectrum of (GE₇-*b*-PCAE₄-*b*-PNIPAM₅₉-*co*-AAc_{2%})₃ in CDCl₃.



Figure S21. ¹H-NMR (400 MHz) spectrum of (PCAE₂-*b*-PNIPAM₇₅)₄ copolymer in CDCl₃.





Figure S23. Hydrodynamic diameter (D_h) for $(GE_7-b-PCAE_4-b-PNIPAM_{79})_3$ copolymer at different concentrations (0.5 to 8 mg/mL in PBS) by DLS at 25 °C.

References:

[1] Pal, S.; Roy, G.; De, P. Polym. Chem. **2014**, *5*, 1275-1284.